Top

Journal of Ovarian Research

Published in:

Open Access 01-12-2021 | Ovarian Cancer | Research

LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer

Authors: Li-yuan Feng, Yong-zhi Huang, Wei Zhang, Li Li

Published in: Journal of Ovarian Research | Issue 1/2021

Abstract

Objective

LAMA3 is a widely studied methylated gene in multiple tumors, but the relationship between chemotherapy resistance in ovarian cancer is unclear. In this study, LAMA3 methylation was predicted by bioinformatics, and the ability of LAMA3 methylation to predict the chemotherapy resistance and prognosis of ovarian cancer was confirmed in experiments.

Methods

Multiple databases have performed the bioinformatics analysis of methylation and transcription factor binding site (TFBS) on the promoter region of LAMA3 gene. Pyrosequencing detected the methylation of LAMA3. QRT-PCR and immunohistochemistry detected the expression of LAMA3. Real Time Cell Analyzer (RTCA) detects changes in cell proliferation, migration and invasion ability. Flow cytometry was used to detect apoptosis.

Results

CPG islands of 176 bp, 134 bp, 125 bp and 531 bp were predicted in the promoter region of LAMA3 gene. The 4 prediction results are basically overlapped. 7 transcription factor binding sites were predicted, and the one with the highest score was on the predicted CpG island located in the proximal promoter region. LAMA3 hypermethylation and low expression are both associated with chemotherapy resistance and poor prognosis in ovarian cancer. LAMA3 methylation was negatively correlated with expression. After upregulation of LAMA3, the proliferation ability of chemoresistant ovarian cancer cell decreased, while the ability of apoptosis, invasion and migration increased.

Conclusion

LAMA3 hypermethylation is associated with chemotherapy resistance and poor prognosis. As a typical CpG island gene, LAMA3(cg20937934) and LAMA3(cg13270625) hypermethylation is negatively correlated with low expression. LAMA3 promotes the invasion, migration and apoptosis of SKOV3DDP. In the future, the mechanism of LAMA3 methylation in ovarian cancer will need to be further studied.

Available only for authorised users

Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer [J]. Lancet. 2019;393(10177):1240–53. https://doi.org/10.1016/S0140-6736(18)32552-2.CrossRefPubMed

Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian Cancer Prevention and Screening [J]. Obstet Gynecol. 2018;131(5):909–27. https://doi.org/10.1097/AOG.0000000000002580.CrossRefPubMed

Orr B, Edwards RP. Diagnosis and Treatment of Ovarian Cancer [J]. Hematol Oncol Clin North Am. 2018;32(6):943–64. https://doi.org/10.1016/j.hoc.2018.07.010.CrossRefPubMed

Norouzi-Barough L, Sarookhani MR, Sharifi M, et al. Molecular mechanisms of drug resistance in ovarian cancer [J]. J Cell Physiol. 2018;233(6):4546–62. https://doi.org/10.1002/jcp.26289.CrossRefPubMed

Jiang X, Li X, Li W, et al. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms [J]. J Cell Mol Med. 2019;23(4):2303–13. https://doi.org/10.1111/jcmm.14133.CrossRefPubMedPubMedCentral

van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment [J]. Endocr Relat Cancer. 2018;25(5):R303–18. https://doi.org/10.1530/ERC-17-0336.CrossRefPubMed

Christie EL, Bowtell DDL. Acquired chemotherapy resistance in ovarian cancer [J]. Ann Oncol. 2017;28(suppl_8):viii13–5.CrossRef

Freimund AE, Beach JA, Christie EL, et al. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer [J]. Hematol Oncol Clin North Am. 2018;32(6):983–96. https://doi.org/10.1016/j.hoc.2018.07.007.CrossRefPubMed

Michalak EM, Burr ML, Bannister AJ, et al. The roles of DNA, RNA and histone methylation in ageing and cancer [J]. Nat Rev Mol Cell Biol. 2019;20(10):573–89. https://doi.org/10.1038/s41580-019-0143-1.CrossRefPubMed

10.

Moore LD, Le T, Fan G. DNA methylation and its basic function [J]. Neuropsychopharmacology. 2013;38(1):23–38. https://doi.org/10.1038/npp.2012.112.CrossRefPubMed

11.

Zhu H, Wang G, Qian J. Transcription factors as readers and effectors of DNA methylation [J]. Nat Rev Genet. 2016;17(9):551–65. https://doi.org/10.1038/nrg.2016.83.CrossRefPubMedPubMedCentral

12.

Tian H, Yan L, Xiao-Fei L, et al. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer [J]. Clin Epigenetics. 2019;11(1):153. https://doi.org/10.1186/s13148-019-0748-4.CrossRefPubMedPubMedCentral

13.

Lund RJ, Huhtinen K, Salmi J, et al. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer [J]. Sci Rep. 2017;7(1):1469. https://doi.org/10.1038/s41598-017-01624-4.CrossRefPubMedPubMedCentral

14.

Hentze JL, Hogdall CK, Hogdall EV. Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?[J]. Mol Clin Oncol. 2019;10(3):323–30. https://doi.org/10.3892/mco.2019.1800.CrossRefPubMedPubMedCentral

15.

Feng LY, Chen CX, Li L. Hypermethylation of tumor suppressor genes is a risk factor for poor prognosis in ovarian cancer: A meta-analysis [J]. Medicine (Baltimore). 2019;98(8):e14588. https://doi.org/10.1097/MD.0000000000014588.CrossRef

16.

Natanzon Y, Goode EL, Cunningham JM. Epigenetics in ovarian cancer [J]. Semin Cancer Biol. 2018;51:160–9. https://doi.org/10.1016/j.semcancer.2017.08.003.CrossRefPubMed

17.

Matei D, Nephew KP. Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes [J]. Cancer Res. 2020;80(18):3775–85. https://doi.org/10.1158/0008-5472.CAN-19-3837.CrossRefPubMedPubMedCentral

18.

Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress [J]. Clin Epigenetics. 2019;11(1):7. https://doi.org/10.1186/s13148-018-0602-0.CrossRefPubMedPubMedCentral

19.

Oza AM, Matulonis UA, Secord AA, et al. A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinumresistant, recurrent ovarian cancer [J]. Clin Cancer Res. 2020;26(5):1009–16. https://doi.org/10.1158/1078-0432.CCR-19-1638.

20.

Matei D, Ghamande S, Roman L, et al. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses [J]. Clin Cancer Res. 2018;24(10):2285–93. https://doi.org/10.1158/1078-0432.CCR-17-3055.CrossRefPubMedPubMedCentral

21.

Zhang Y, Mei Q, Liu Y, et al. The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer [J]. Oncoimmunology. 2017;6(9):e1323619. https://doi.org/10.1080/2162402X.2017.1323619.CrossRefPubMedPubMedCentral

22.

Fang F, Cardenas H, Huang H, et al. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs [J]. Cancer Res. 2018;78(3):631–44. https://doi.org/10.1158/0008-5472.CAN-17-1492.CrossRefPubMed

23.

Pan Z, Li L, Fang Q, et al. Analysis of dynamic molecular networks for pancreatic ductal adenocarcinoma progression [J]. Cancer Cell Int. 2018;18(1):214. https://doi.org/10.1186/s12935-018-0718-5.CrossRefPubMedPubMedCentral

24.

Ii M, Yamamoto H, Taniguchi H, et al. Co-expression of laminin beta3 and gamma2 chains and epigenetic inactivation of laminin alpha3 chain in gastric cancer [J]. Int J Oncol. 2011;39(3):593–9. https://doi.org/10.3892/ijo.2011.1048.CrossRefPubMed

25.

Moller-Levet CS, Betts GN, Harris AL, et al. Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis [J]. PLoS Comput Biol. 2009;5(11):e1000571. https://doi.org/10.1371/journal.pcbi.1000571.CrossRefPubMedPubMedCentral

26.

Xu SF, Zheng Y, Zhang L, et al. Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma [J]. Mol Ther Nucleic Acids. 2019;18:166–82. https://doi.org/10.1016/j.omtn.2019.08.005.CrossRefPubMedPubMedCentral

27.

Peng X, Yu M, Chen J. Transcriptome sequencing identifies genes associated with invasion of ovarian cancer [J]. J Int Med Res. 2020;48(9):300060520950912. https://doi.org/10.1177/0300060520950912.CrossRefPubMed

28.

Tang L, Wang P, Wang Q, et al. Correlation of LAMA3 with onset and prognosis of ovarian cancer [J]. Oncol Lett. 2019;18(3):2813–8. https://doi.org/10.3892/ol.2019.10600.CrossRefPubMedPubMedCentral

29.

Meng Q, Duan P, Li L, et al. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer [J]. Tohoku J Exp Med. 2018;244(4):291–6. https://doi.org/10.1620/tjem.244.291.CrossRefPubMed

30.

Phillips-Chavez C, Watson M, Coward J, et al. A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients [J]. Eur J Clin Pharmacol. 2020;76(8):1059–74. https://doi.org/10.1007/s00228-020-02874-4.CrossRefPubMed

31.

Sathyanarayana UG, Padar A, Huang CX, et al. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma [J]. Clin Cancer Res. 2003;9(17):6389–94.PubMed

32.

Mullapudi N, Yye B, Suzuki M, et al. Genome Wide Methylome Alterations in Lung Cancer [J]. PLoS One. 2015;10(12):e0143826. https://doi.org/10.1371/journal.pone.0143826.CrossRefPubMedPubMedCentral

33.

Sathyanarayana UG, Maruyama R, Padar A, et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes [J]. Cancer Res. 2004;64(4):1425–30. https://doi.org/10.1158/0008-5472.CAN-03-0701.CrossRefPubMed

34.

Pouliot N, Kusuma N. Laminin-511: a multi-functional adhesion protein regulating cell migration, tumor invasion and metastasis [J]. Cell Adhes Migr. 2013;7(1):142–9. https://doi.org/10.4161/cam.22125.CrossRef

35.

Choi MR, An CH, Yoo NJ, et al. Laminin gene LAMB4 is somatically mutated and expressionally altered in gastric and colorectal cancers [J]. APMIS. 2015;123(1):65–71. https://doi.org/10.1111/apm.12309.CrossRefPubMed

36.

Xu Y, Wang S, Chan HF, et al. Dihydromyricetin Induces Apoptosis and Reverses Drug Resistance in Ovarian Cancer Cells by p53-mediated Downregulation of Survivin [J]. Sci Rep. 2017;7(1):46060. https://doi.org/10.1038/srep46060.CrossRefPubMedPubMedCentral

37.

Li X, Chen W, Jin Y, et al. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes [J]. Biochem Pharmacol. 2019;161:98–112. https://doi.org/10.1016/j.bcp.2019.01.009.CrossRefPubMed

38.

Rada M, Nallanthighal S, Cha J, et al. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer [J]. Oncogene. 2018;37(35):4809–20. https://doi.org/10.1038/s41388-018-0297-x.CrossRefPubMed

39.

Wang H, Luo Y, Qiao T, et al. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion [J]. J Ovarian Res. 2018;11(1):93. https://doi.org/10.1186/s13048-018-0468-y.CrossRefPubMedPubMedCentral

Title: LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer
Authors: Li-yuan Feng
Yong-zhi Huang
Wei Zhang
Li Li
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Ovarian Cancer
Ovarian Cancer
Cytostatic Therapy
Published in: Journal of Ovarian Research / Issue 1/2021
Electronic ISSN: 1757-2215
DOI: https://doi.org/10.1186/s13048-021-00807-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis

CXCL14 facilitates the growth and metastasis of ovarian carcinoma cells via activation of the Wnt/β-catenin signaling pathway

Long non-coding RNA AFAP1-AS1 facilitates ovarian cancer progression by regulating the miR-107/PDK4 axis

Ovarian sex cord stromal tumours: analysis of the clinical and sonographic characteristics of different histopathologic subtypes

Abnormalities of early folliculogenesis and serum anti-Müllerian hormone in chinese patients with polycystic ovary syndrome

Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report